Multinational phase 3 trial of momelotinib versus danazol in symptomatic patients with anemia and myelofibrosis

Janus kinase (JAK) inhibitors approved to myelofibrosis provide spleen and symptom improvements but do not meaningfully improve anemia. Momelotinib is a first-in-class inhibitor of activin A receptor type 1 as well as JAK1 and JAK2. The multinational phase 3 MOMENTUM trial found that among patients with myelofibrosis and anemia, treatment with momelotinib compared with danazol resulted in clinically significant improvements in myelofibrosis-associated symptoms, anemia measures, and spleen response, with favorable safety. The authors conclude that these findings support the future use of momelotinib as an effective treatment in patients with myelofibrosis, especially in those with anemia.